CD133 overexpression in BAKR cells also correlates with the dramatic upregulation of basal levels of anti-apoptotic BCL-2 and down-regulation of the pro-apoptotic BAX protein which may tilt the balance towards increased cell survival upon treatment with targeted melanoma therapeutics. This evidence concerns the gene BCL2 and melanoma.